First-line treatment of metastatic melanoma: role of nivolumab.
Abstract
Historically, the median overall survival of metastatic melanoma patients was less
than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically
shifted this landscape with increased survival rates and the real possibility that
long-term disease control is achievable. Advances in immune modulators, including
cytotoxic T-lymphocyte antigen-4 and programmed death-1 based treatments, have been
an integral part of this success. In this article, we review previous and recent therapeutic
developments for metastatic melanoma patients. We discuss advances in immunotherapy
while focusing on the use of nivolumab alone and in combination with other agents,
including ipilimumab in advanced melanoma. One major goal in melanoma research is
to optimize combination strategies allowing for more patients to experience benefit
while minimizing toxicity. A better understanding of the optimal sequencing, combinations,
and mechanisms underlying the development of resistance may provide evidence for rational
clinical trial designs of novel immunotherapy strategies in melanoma and other cancer
subtypes.
Type
Journal articlePermalink
https://hdl.handle.net/10161/15631Published Version (Please cite this version)
10.2147/ITT.S110479Publication Info
Force, Jeremy; & Salama, April Ks (2017). First-line treatment of metastatic melanoma: role of nivolumab. Immunotargets Ther, 6. pp. 1-10. 10.2147/ITT.S110479. Retrieved from https://hdl.handle.net/10161/15631.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Jeremy M Force
Assistant Professor of Medicine
April Kelly Scott Salama
Associate Professor of Medicine
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info